Photo of Peter Palese

Peter Palese

  • PROFESSOR & CHAIR Microbiology
  • PROFESSOR Medicine, Infectious Diseases
Print ProfilePrint Profile


  • Ph.D., University of Vienna



  • 2015 -
    Beijerinck Virology Prize
    Royal Netherlands Academy of Arts and Sciences

  • 2014 -
    Honorary Doctorate
    Baylor College of Medicine

  • 2014 -
    Elected Fellow of the American Academy of Arts and Sciences

  • 2012 -
    Election to the Institute of Medicine of the National Academy of Sciences

  • 2012 -
    Sanofi–Institut Pasteur Award

  • 2010 -
    European Virology Award (EVA)
    European Society for Virology

  • 2006 -
    Robert Koch Prize

  • 2006 -
    Elected Member
    The German Academy of Sciences Leopoldina

  • 2002 -
    Corresponding Member
    Austrian Academy of Sciences

  • 2000 -
    National Academy of Sciences


The Palese Laboratory focuses on fundamental questions concerning the genetic make-up and biology of viruses, as well as virus-host interactions.  They use molecular biological techniques to understand how viruses replicate and how they interact with cells to cause disease in their hosts.  Emphasis is on the study of RNA viruses, including influenza, paramyxo, and corona viruses.  These are four major research directions in the laboratory at the present time:  (1) by genetically changing influenza viruses via recombinant DNA techniques, they are studying viral genes and gene products to develop a universal influenza virus vaccine; (2) intracellular proteins are identified that interact with viral proteins, and the biological functions of these cellular proteins are studies; (3) attempts are made to develop broad spectrum antivirals and to identify their mechanisms of actions.  

The Palese Laboratory is interested in training students and postdoctoral fellows who will become independent investigators in "molecular" studies of infectious viral diseases.


Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 2015; 6(2).

Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nature reviews. Drug discovery 2015 Feb; 14(3).

Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, Huang M, Qu X, Huang Y, Salgado-Ferrer M, Ho IY, Taylor W, Hai R, Wrammert J, Ahmed R, García-Sastre A, Palese P, Krammer F, Wilson PC. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. The Journal of clinical investigation 2015 Mar; 125(3).

He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. Journal of virology 2015 Apr; 89(7).

Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses. Journal of virology 2015 Mar; 89(6).

Riegger D, Hai R, Dornfeld D, Mänz B, Leyva-Grado V, Sánchez-Aparicio MT, Albrecht RA, Palese P, Haller O, Schwemmle M, García-Sastre A, Kochs G, Schmolke M. The nucleoprotein of newly emerged H7N9 influenza A virus harbors a unique motif conferring resistance to antiviral human MxA. Journal of virology 2015 Feb; 89(4).

Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. Journal of virology 2014 Dec; 88(23).

Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Journal of virology 2014 Nov; 88(22).

Krammer F, Palese P, Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Current topics in microbiology and immunology 2015; 386.

Heaton NS, Langlois RA, Sachs D, Lim JK, Palese P, tenOever BR. Long-term survival of influenza virus infected club cells drives immunopathology. The Journal of experimental medicine 2014 Aug; 211(9).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Palese during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Avimex; ContraFect Corporation; Farmak; Forge Life Sciences, LLC; Kadmon Corporation, LLC; MedImmune, LLC; Novartis

Royalty Payments:

  • Avimex; MedImmune, LLC

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • ContraFect Corporation; Forge Life Sciences, LLC; Vivaldi Biosciences Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Annenberg Building Floor 16 Room 16-20
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-7318
Fax: 212-722-3634